CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the company’s PurISTSM algorithmic test has received a ...
Tempus AI (TEM) announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a ...
CHICAGO, January 27, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study ...
Tempus AI has an immunology risk testing product ready for researchers to test out and is working with Cleveland Clinic on better ways to assess how immunotherapy might work on patients. The ...
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results